The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.

At the outset of the new year, J.P. Morgan adjusted its ratings for brokers, asset managers and exchanges, favoring brokers ...

The J.P. Morgan Healthcare Conference attracts thousands of attendees each year from the provider, insurance, digital health ...

J.P. Morgan Asset Management’s Michael Cembalest calls them “Alchemists” — the Trump White House nominees who are looking to ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced ...

J.P. Morgan releases its annual look-ahead days before the entire biopharma industry descends on San Francisco for the annual ...

J.P. Morgan analyst Doug Anmuth said he sees room for Alphabet, Google’s parent, to gain ground on a variety of fronts, ...

Like many other major companies, especially those in finance, JPMorgan is making the push for more in-person work.

The company sought damages against Edward Turley, a former employee who was subject to more than a dozen customer complaints.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Josh Forstater has joined J.P. Morgan Asset Management as managing director, head of Everyday 401 (k), a retirement plan ...